Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 72,23 € (+41,07 %). Medianen er 72,23 € (+41,07 %).
| Køb |
11 |
| Behold |
1 |
| Sælg |
1 |
Nyheder Til nyhedsfeedet
TG Therapeutics raises revenue outlook, BRIUMVI gains market share in RMS
TG Therapeutics reports strong commercial growth of BRIUMVI in relapsing multiple sclerosis and raises its 2024 revenue guidance to $890–905 million; the company is targeting a $1 billion run rate by the end of Q4. BRIUMVI has captured more than one-third of the IV anti‑CD20 market, a simplified IV dosing regimen should ease use, and a sBLA is upcoming. A subcutaneous formulation showed about 60% bioavailability in Phase I and will be tested in Phase III against two dosing intervals; TG sees broad potential also in myasthenia gravis and treatment‑resistant schizophrenia. » Mere på de.investing.com
TG Therapeutics stock recovers despite earnings miss
TG Therapeutics shares rose intraday by 5.9%, extending the recovery after the sharp sell-off following the Q2 results. The company reported EPS of $0.05 versus a consensus of about $0.44; the miss was due to higher manufacturing and operating costs, not weak revenue. Revenue increased in the second quarter to roughly $240 million (+70% YoY) and the full-year guide was raised to about $950 million; additionally, the completed enrollment of the phase-3 trial for subcutaneous BRIUMVI administration could be another catalyst. » Mere på de.investing.com
TG Therapeutics climbs after Briumvi outperforms expectations and positive subcutaneous data
ClearBridge's Q2 investor letter named TG Therapeutics as a top contributor after its key drug Briumvi delivered greater-than-expected growth and positive clinical results for a subcutaneous formulation that could expand the addressable market. The stock has risen sharply over the past month and year, reflecting renewed investor interest in the company's commercial-stage multiple sclerosis franchise. » Mere på finance.yahoo.com
Virksomhedstal
| (EUR) | juni 2026 | YoY |
|---|---|---|
| Omsætning | 210,58 mio. | 75,85 % |
| Bruttofortjeneste | 174,49 mio. | 68,29 % |
| Nettoresultat | 6,82 mio. | 71,49 % |
| EBITDA | 19,08 mio. | 40,36 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 7,88 mia. € |
Antal aktier | 153,08 mio. |
Højeste/laveste i 52 uger | 53,21 € - 24,01 € |
| Udbytte | Nej |
Beta | 1,80 |
P/E (PE Ratio) | 18,85 |
PEG (PEG Ratio) | 0,03 |
K/I (PB Ratio) | 13,47 |
P/S (PS Ratio) | 10,99 |
Virksomhedsprofil
TG Therapeutics, Inc., et kommercielt biofarmaceutisk selskab, fokuserer på erhvervelse, udvikling og kommercialisering af nye behandlinger for B-celle-maligniteter og autoimmune sygdomme. Selskabets terapeutiske produktkandidater omfatter Ublituximab, et undersøgelsesstadie glycoengineeret monoklonalt antistof til behandling af B-celle non-Hodgkin-lymfom, kronisk lymfocytisk leukæmi (CLL) og recidiverende former for multipel sklerose; og Umbralisib, en oral hæmmer af PI3K-delta og CK1-epsilon til behandling af CLL, marginalzonelymfom og follikulært lymfom. Selskabet udvikler desuden Cosibelimab, et humant monoklonalt antistof af IgG1-subtypen, der binder sig til programmed death-ligand 1 (PD-L1) og blokerer dets interaktioner med PD-1- og B7.1-receptorerne; TG-1701 er en oralt tilgængelig og kovalent bundet Bruton's tyrosinkinase (BTK)-hæmmer, der i in vitro-kinasescreeninger viser selektivitet over for BTK sammenlignet med ibrutinib; og TG-1801, et bispecifikt CD47- og CD19-antistof. Derudover har selskabet forskellige licenserede prækliniske programmer for BET, interleukin-1-receptorassocieret kinase-4 og GITR; samt samarbejdsaftaler med Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated og Jubilant Biosys. Selskabet har strategiske alliancer med LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd. og Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. blev stiftet i 1993 og har hovedkontor i New York, New York.
| Navn | TG Therapeutics |
| CEO | Michael S. Weiss |
| Hjemsted | Morrisville,
ny USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Bioteknologi |
| Børsnotering | 03.05.2010 |
| Medarbejdere | 399 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | TGTX |
London Stock Exchange | 0VGI.L |
Frankfurt | NKB2.F |
Düsseldorf | NKB2.DU |
London | 0VGI.L |
SIX | NKB2.SW |
München | NKB2.MU |
